2026 -
now Board Member, Audit Committee Chair and Compensation Committee Member @ First Tracks Biotherapeutics (Nasdaq: TRAXV)
2026 -
now Board Member and Audit Chair @ Helix Acquisition Corp. III (Nasdaq: HLXC)
2025 -
now Board Member and Audit Chair @
2020 -
now Board Member, Audit Committee Chair and Compensation Committee Member @ Design Therapeutics (Nasdaq: DSGN)
2015 -
now Board Member, Audit Committee Chair and Compensation Committee Member @ AnaptysBio (Nasdaq: ANAB)
1989 -
now Chairman @
2024 -
2025 Board Member and Audit Chair @ Helix Acquisiton Corp. II (Nasdaq: HLXB - SPAC merged with BridgeBio Oncology Th
2017 -
2025 Board Member, Audit Committee Chair, and Compensation Committee Member @ Xeris Pharmaceuticals, Inc. (Nasdaq: XERS)
2018 -
2025 Board Member, Audit Committee Chair, Nom and Gov Committee Member and Lead Independent Director @ Poseida Therapeutics, Inc. (Nasdaq: PSTX - Acquired by Roche)
John Schmid, based in Rancho Santa Fe, CA, US, is currently a Board Member and Audit Chair at BlossomHill Therapeutics, Inc.. John Schmid brings experience from previous roles at First Tracks Biotherapeutics (Nasdaq: TRAXV), Helix Acquisition Corp. III (Nasdaq: HLXC), Bright Peak Therapeutics and Design Therapeutics (Nasdaq: DSGN). John Schmid holds a 1990 - 1992 MBA @ University of San Diego. With a robust skill set that includes Biotechnology, Life Sciences, Start-ups, Financial Modeling, Investor Relations and more. John Schmid has 1 emails and 1 mobile phone numbers on RocketReach.
Get contact details of over 700M profiles across 60M companies - all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.